Ketamine and esketamine (“es/ketamine”) treatment protocols have been investigated in patients’ samples with treatment-refractory anxiety disorders. We systematically reviewed publications in which es/ketamine was used to treat anxiety symptoms in the context of either Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) anxiety disorders or treatment-resistant depression (TRD).
Method:
The literature search of English-language studies combining each of the keywords “ketamine” or “esketamine” with various psychopathological terms produced 4086 results. Through the use of specific inclusion/exclusion criteria, a total of 78 studies were eligible for inclusion.
Results:
Eleven studies investigated ketamine pharmacotherapy (no esketamine study was found) of patients suffering primarily from a DSM-5 anxiety disorder. Additionally, we found 67 studies which: (a) reported es/ketamine pharmacotherapy for treating primarily unipolar/bipolar depression and secondarily assessed changes in anxiety symptoms (N = 55); or (b) compared the outcome (depression/suicidality severity) of es/ketamine between “anxious” versus “non-anxious” TRD (N = 12). These studies were notably heterogeneous, and included randomized controlled trials, crossover trials, open-label studies, and case reports. Methods of administration of ketamine varied, including subcutaneous, intravenous, intramuscular, and oral; outcome measures also varied. Study findings suggest that es/ketamine is associated with a reduction of anxiety in the context either of anxiety disorders or of unipolar/bipolar TRD. These effects are sustained, especially with repeated doses and maintenance treatment: however, after terminating maintenance treatment anxiety symptoms may soon re-emerge. The tablet formulation reduces anxiety more slowly, but with fewer side effects.
Conclusion:
There are indications that es/ketamine pharmacotherapy may reduce pathological anxiety, although relapse may follow its termination. More studies are needed to confirm these preliminary findings.
AbuhelwaAYSomogyiAALooCK, et al. (2022) Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression. Clinical Pharmacology & Therapeutics112(3): 720–729.
2.
AhujaSBrendleMSmartL, et al. (2022) Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: A retrospective descriptive cohort study. BMC Psychiatry22(1): 634.
3.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association.
4.
AmiazRSaportaRNoyA, et al. (2021) Can quetiapine prolong the antidepressant effect of ketamine?: A 5-year follow-up study. Journal of Clinical Psychopharmacology41(6): 673–675.
5.
BaldwinDSEvansDLHirschfeldRM, et al. (2002) Can we distinguish anxiety from depression?Psychopharmacology Bulletin36(Suppl. 2): 158–165.
6.
BallardEIonescuDVande VoortJL, et al. (2014) Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety. Journal of Psychiatric Research58: 161–166.
7.
BandelowBAllgulanderCBaldwinDS, et al. (2023) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders. World Journal of Biological Psychiatry24(2): 79–117.
8.
BanovMDYoungJRDunnT, et al. (2020) Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: A review of the literature. CNS Spectrums25(3): 331–342.
9.
BonnettCJJainRRossCN, et al. (2021) Intramuscular ketamine to treat major depressive disorder: A case series of forty patients. Journal of Psychiatric and Mental Health Nursing6(2): 145.
10.
BorentainSGogateJWilliamsonD, et al. (2022) Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. International Journal of Methods in Psychiatric Research31(4): e1927.
11.
BrendleMAhujaSValleMD, et al. (2022) Safety and effectiveness of intranasal esketamine for treatment-resistant depression: A real-world retrospective study. Journal of Comparative Effectiveness Research11(18): 1323–1336.
12.
CaddyCGiaroliGWhiteTP, et al. (2014) Ketamine as the prototype glutamatergic antidepressant: Pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Therapeutic Advances in Psychopharmacology4(2): 75–99.
13.
CastleCGrayANeehoffS, et al. (2017) Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology31(10): 1306–1311.
14.
ChenMHLinWCWuHJ, et al. (2021a) Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. CNS Spectrums26(4): 362–367.
15.
ChenMHWuHJLiCT, et al. (2021b) Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: Post hoc pooled analyses of randomized placebo-controlled and open-label trials. Journal of Affective Disorders281: 865–871.
16.
ChisamoreNDanayanKRodriguesNB, et al. (2023) Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth. Journal of Psychopharmacology37(8): 775–783.
17.
CostiSVan DamNTMurroughJW (2015) Current status of ketamine and related therapies for mood and anxiety disorders. Current Behavioral Neuroscience Reports2(4): 216–225.
18.
DalyEJTurkozISalvadoreG, et al. (2021) The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. Depression and Anxiety38(11): 1120–1130.
19.
DanayanKChisamoreNRodriguesNB, et al. (2023) Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Research323: 115133.
20.
d’AndreaGChiappiniSMcIntyreRS, et al. (2023) Investigating the effectiveness and tolerability of intranasal esketamine among older adults with treatment-resistant depression (TRD): A post-hoc analysis from the REAL-ESK study group. American Journal of Geriatric Psychiatry31(12): 1032–1041.
21.
de FilippisRDe FazioP (2023) Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: A case report. Bipolar Disorders25(6): 524–526.
22.
DiazgranadosNIbrahimLBrutscheNE, et al. (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry67(8): 793–802.
23.
DomschkeKDeckertJAroltV, et al. (2010) Anxious versus non-anxious depression: Difference in treatment outcome. Journal of Psychopharmacology24(4): 621–622.
24.
DomschkeKSeulingPDSchieleMA, et al. (2024) The definition of treatment resistance in anxiety disorders: A Delphi method-based consensus guideline. World Psychiatry23(1): 113–123.
25.
DumanRS (2014) Neurobiology of stress, depression, and rapid acting antidepressants: Remodeling synaptic connections. Depression and Anxiety31(4): 291–296.
26.
DunnerDLFugateRMDemopulosCM (2020) Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: A case report. Neurology, Psychiatry and Brain Research36: 30–31.
27.
DuttonMCanATBeaudequinD, et al. (2022) Oral ketamine reduces the experience of stress in people with chronic suicidality. Journal of Affective Disorders300: 410–417.
28.
FalkESchlieperDvan CasterP, et al. (2020) A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: A retrospective pilot study. BMC Palliative Care19(1): 1.
29.
FancyFRodriguesNBDi VincenzoJD, et al. (2023) Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. Bipolar Disorders25(2): 99–109.
30.
FavaMAlpertJECarminCN, et al. (2004) Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychological Medicine34(7): 1299–1308.
31.
FavaMRushAJAlpertJE, et al. (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. American Journal of Psychiatry165(3): 342–351.
32.
FedgchinMTrivediMDalyEJ, et al. (2019) Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: Results of a randomized, double-blind, active-controlled study (TRANSFORM-1). International Journal of Neuropsychopharmacology22(10): 616–630.
33.
FeulnerLSermchaiwongTRodlandN, et al. (2023) Efficacy and safety of psychedelics in treating anxiety disorders. Ochsner Journal23(4): 315–328.
34.
FortressAMSmithIMPangKCH (2018) Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: Implications for the pathophysiology and treatment of anxiety disorders. Neuropharmacology137: 372–381.
35.
FuDJIonescuDFLiX, et al. (2020) Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: Double-blind, randomized study (ASPIRE I). Journal of Clinical Psychiatry81(3): 19m13191.
36.
GellerJKeithKSmithC, et al. (2024) Response to ketamine treatment for major depressive disorder not associated with number of psychiatric comorbidities. Journal of Affective Disorders Reports15: 100688.
37.
GluePMedlicottNJHarlandS, et al. (2017) Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology31(10): 1302–1305.
38.
GluePMedlicottNJNeehoffS, et al. (2020a) Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: Open label pilot study. Therapeutic Advances in Psychopharmacology10: 2045125320922474.
39.
GluePNeehoffSBeagleholeB, et al. (2024) Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. Journal of Psychopharmacology38(2): 162–167.
40.
GluePNeehoffSMMedlicottNJ, et al. (2018) Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalized anxiety and social anxiety disorders. Journal of Psychopharmacology32(6): 663–667.
41.
GluePNeehoffSSabadelA, et al. (2020b) Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology34(3): 267–272.
42.
HampfCScherf-ClavelMWeißC, et al. (2023) Effects of anxious depression on antidepressant treatment response. International Journal of Molecular Sciences24(24): 17128.
43.
HartlandHMahdaviKJelenLA, et al. (2023) A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects. Journal of Psychopharmacology37(8): 764–774.
44.
HassanKStruthersWMSankarabhotlaA, et al. (2022) Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use. Front in Psychiatry13: 992624.
45.
HietamiesTMMcInnesLAKliseAJ, et al. (2023) The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. Journal of Affective Disorders335: 484–492.
46.
HochschildAKeilpJGMaddenSP, et al. (2022) Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression. Journal of Affective Disorders300: 10–16.
47.
HullTDMalgaroliMGazzaleyA, et al. (2022) At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. Journal of Affective Disorders314: 59–67.
48.
IonescuDFNiciuMJMathewsDC, et al. (2013) Neurobiology of anxious depression: A review. Depression and Anxiety30(4): 374–385.
49.
IonescuDFLuckenbaughDANiciuMJ, et al. (2014) Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. Journal of Clinical Psychiatry75(9): e932–e938.
50.
IonescuDFLuckenbaughDANiciuMJ, et al. (2015) A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disorders17(4): 438–443.
51.
IonescuDFFuDJQiuX, et al. (2021) Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: Results of a phase 3, double-blind, randomized study (ASPIRE II). International Journal of Neuropsychopharmacology24(1): 22–31.
52.
IrwinSAIglewiczA (2010) Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. Journal of Palliative Medicine13(7): 903–908.
53.
IrwinSAIglewiczANelesenRA, et al. (2013) Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: A 28-day open-label proof-of-concept trial. Journal of Palliative Medicine16(8): 958–965.
54.
JamiesonCCanusoCMIonescuDF, et al. (2023) Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: A pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II). Quality of Life Research32(11): 3053–3061.
55.
Karbasi AmelAHosseiniF (2023) A Comparison of the anti-anxiety effects of oral ketamine and fluvoxamine in children with separation anxiety disorder manifesting as school refusal. Advanced Biomedical Research12: 110.
56.
KimJLeeSHShinC, et al. (2024) A multi-center, open-label, single-arm study to investigate the early effectiveness of esketamine nasal spray in patients with treatment-resistant depression using a mobile self-monitoring application. Pharmaceuticals (Basel)17(9): 1143.
57.
KleinDF (1993) False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Archives of General Psychiatry50(4): 306–317.
58.
KolarD (2018) Addictive potential of novel treatments for refractory depression and anxiety. Neuropsychiatric Disease and Treatment14: 1513–1519.
59.
KonstantakopoulosGMasdrakisVGMarkianosM, et al. (2013) On the differential diagnosis of anxious from nonanxious major depression by means of the Hamilton Scales. Scientific World Journal2013: 294516.
60.
LanXWangCZhangF, et al. (2023) Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression. General Psychiatry36(3): e101007.
61.
LapidusKALevitchCFPerezAM, et al. (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry76(12): 970–976.
62.
LiangYYouZChenX, et al. (2024) Long-term quality of life after repeated ketamine infusions in anxious and nonanxious patients with depression. Journal of Affective Disorders349: 394–399.
63.
LipsitzOMcIntyreRSRodriguesNB, et al. (2021) Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Psychiatric Research136: 444–451.
64.
LipsitzOMcIntyreRSRodriguesNB, et al. (2022) Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence. CNS Spectrums27(3): 322–330.
65.
LiuWZhouYZhengW, et al. (2019) Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. Journal of Affective Disorders259: 1–6.
66.
LooCGlozierNBartonD, et al. (2023) Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial. British Journal of Psychiatry223(6): 533–541.
67.
LuccheseACSarinLMMagalhãesEJM, et al. (2021). Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. Journal of Psychopharmacology35(2): 142–149.
68.
MalhiGSLeUKaufmannC, et al. (2024) Adding esketamine to lamotrigine to treat major depression: Combinatorial synergism, augmentation, or neither?Bipolar Disorders26(5): 500–504.
69.
MandalSSinhaVKGoyalN (2019) Efficacy of ketamine therapy in the treatment of depression. Indian Journal of Psychiatry61(5): 480–485.
70.
MarshallRValleKSheridanD, et al. (2023) Ketamine for treatment-resistant depression and suicidality in adolescents: An observational study of 3 cases. Journal of Clinical Psychopharmacology43(5): 460–462.
71.
MartinottiGDell’OssoBDi LorenzoG, et al.; REAL-ESK Study Group (2023) Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar Disorders25(3): 233–244.
72.
MartinottiGVitaAFagioliniA, et al.; REAL-ESK Study Group (2022) Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study). Journal of Affective Disorders319: 646–654.
73.
McIntyreRSLipsitzORodriguesNB, et al. (2020a) The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disorders22(8): 831–840.
74.
McIntyreRSRodriguesNBLeeY, et al. (2020b) The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Affective Disorders274: 903–910.
75.
McIntyreRSRodriguesNBLipsitzO, et al. (2021) The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Psychopharmacology35(2): 128–136.
76.
MikellidesGMichaelPPsaltaL, et al. (2022) A retrospective naturalistic study comparing the efficacy of ketamine and repetitive transcranial magnetic stimulation for treatment-resistant depression. Frontiers in Psychiatry12: 784830.
77.
MyersKMCarlezonWADavisM (2011) Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology36(1): 274–293.
78.
NasirMTrujilloDLevineJ, et al. (2022) Glutamate systems in DSM-5 anxiety disorders: Their role and a review of glutamate and GABA psychopharmacology. Frontiers in Psychiatry11: 548505.
79.
OliverPASnyderADFeinnR, et al. (2022) Clinical effectiveness of intravenous racemic ketamine infusions in a large community sample of patients with treatment-resistant depression, suicidal ideation, and generalized anxiety symptoms: A retrospective chart review. Journal of Clinical Psychiatry83(6): 21m14336.
80.
OulisPMasdrakisVGMarkianosM (2014) Testosterone and dehydroepiandrosterone sulfate in female anxious and non-anxious major depression. International Journal of Psychiatry in Clinical Practice18(1): 21–24.
81.
PageMJMcKenzieJEBossuytPM, et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ372(71): 1-9.
82.
PapolosDFreiMRossignolD, et al. (2018) Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype. Journal of Affective Disorders225: 545–551.
83.
PapolosDFTeicherMHFaeddaGL, et al. (2013) Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype. Journal of Affective Disorders147(1–3): 431–436.
84.
PepeMBartolucciGMarcelliI, et al. (2023a) Reduction in cognitive symptoms following intranasal esketamine administration in patients with chronic treatment-resistant depression: A 12-week case series. Journal of Psychiatric Practice29(4): 325–332.
85.
PepeMBartolucciGMarcelliI, et al. (2023b) The patient’s perspective on the effects of intranasal esketamine in treatment-resistant depression. Brain Sciences13(10): 1494.
86.
PettorrusoMGuidottiRd’AndreaG, et al.; REAL-ESK Study Group(2023) Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING). Psychiatry Research327: 115378.
87.
PopovaVDalyEJTrivediM, et al. (2019) Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. American Journal of Psychiatry176(6): 428–438.
88.
RasmussenKG (2016) Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety. Progress in Neuropsychopharmacology & Biological Psychiatry64: 218–224.
89.
RaySMKiousBM (2016) Sustained resolution of panic disorder, agoraphobia, and generalized anxiety disorder with a single ketamine infusion: A case report. Primary Care Companion for CNS Disorders18(4). https://doi.org/10.4088/pcc.15l01899
90.
RodriguesNBMcIntyreRSLipsitzO, et al. (2020) Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. Journal of Affective Disorders276: 570–575.
91.
RodriguesNBSiegelALipsitzO, et al. (2022) Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. CNS Spectrums27(3): 315–321.
92.
SalloumNCFavaMFreemanMP, et al. (2019) Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depression and Anxiety36(3): 235–243.
93.
SalvadoreSvan der VeenJWZhangY, et al. (2012) An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. International Journal of Neuropsychopharmacology15(8): 1063–1072.
94.
ShadliSMKaweTMartinD, et al. (2018) Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. International Journal of Neuropsychopharmacology21(8): 717–724.
95.
SolisECvan HemertAMCarlierIVE, et al. (2021) The 9-year clinical course of depressive and anxiety disorders: New NESDA findings. Journal of Affective Disorders295: 1269–1279.
96.
TalaeiAFarid HoseiniFMahdaviM, et al. (2023) A comparison between single and double-dose intravenous ketamine administration in bipolar mood disorder: A double-blind controlled clinical trial. Iranian Journal of Psychiatry18(4): 396–405.
97.
TaylorJHLanderos-WeisenbergACoughlinC, et al. (2018) Ketamine for social anxiety disorder: A randomized placebo-controlled crossover trial. Neuropsychopharmacology43(2): 325–333.
98.
Truppman LattieDNehoffHNeehoffS, et al. (2021) Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. Journal of Psychopharmacology35(2): 137–141.
99.
TullyJLDahlénADHaggartyCJ, et al. (2022) Ketamine treatment for refractory anxiety: A systematic review. British Journal of Clinical Pharmacology88(10): 4412–4426.
100.
TurkozINelsonJCWilkinsonST, et al. (2023) Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Research323: 115165.
101.
VasavadaMMLoureiroJKubickiA, et al. (2021) Effects of serial ketamine infusions on corticolimbic functional connectivity in major depression. Biological Psychiatry, Cognitive Neuroscience and Neuroimaging6(7): 735–744.
102.
VidalSGex-FabryMBancilaV, et al. (2018) Efficacy and safety of a rapid intravenous injection of ketamine 0.5 mg/kg in treatment-resistant major depression: An open 4-week longitudinal study. Journal of Clinical Psychopharmacology38(6): 590–597.
103.
WangCZhouYZhengW, et al. (2019) Association between depression subtypes and response to repeated-dose intravenous ketamine. Acta Psychiatrica Scandinavica140(5): 446–457.
104.
WhittakerEDadabayevARJoshiSA, et al. (2021) Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic Advances in Psychopharmacology11: 20451253211056743.
105.
WilkinsonSTFarmerCBallardED, et al. (2019) Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology44(7): 1233–1238.
106.
WilkowskaAWigluszMSArciszewska-LeszczukA, et al. (2024) Anhedonia in bipolar depression treated with ketamine. Bipolar Disorders26(4): 356–363.
107.
YuanSLuoXChenX, et al. (2023) Functional connectivity differences in the amygdala are related to the antidepressant efficacy of ketamine in patients with anxious depression. Journal of Affective Disorders320: 29–36.
108.
ZarateCAJrBrutscheNEIbrahimL, et al. (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biological Psychiatry71(11): 939–946.
109.
ZhengWYangXHGuLM, et al. (2022) Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. Journal of Affective Disorders313: 72–76.
110.
ZhengWZhouYLLiuWJ, et al. (2018) Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. Journal of Psychiatric Research106: 61–68.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
